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No exact data are available in what percentage of unse-
lected acromegaly patients have a congenital (germline or 
mosaic) cause of their disease. We know, however, that 
almost 50% of childhood-onset cases leading to gigantism 
have a now identifiable genetic background [1, 2].
Tumor development is a complex multistep process 
influenced by genetic, epigenetic and environmental fac-
tors as well as by the tumor microenvironment. In this brief 
overview, we concentrate on the genetic basis of sporadic 
and familial acromegaly while refer to an excellent review 
regarding other molecular mechanisms [3].
Acromegaly can be part of a syndromic disease occur-
ring concomitantly with other endocrine tumors, such as 
in MEN1, MEN4, Carney complex, McCune-Albright and 
SDHx-related pituitary adenomas (Table 1) or presents as 
part of familiar isolated pituitary adenoma (FIPA) in aryl 
hydrocarbon receptor interacting protein (AIP) or GPR101 
(G-protein coupled receptor 101) mutation positive and 
negative cases [4, 5].
Familial isolated pituitary adenomas
Familial isolated pituitary adenoma syndrome is the most 
common familial cause of acromegaly/gigantism, as avail-
able data suggest that syndromic familial acromegaly, due 
to Carney complex, MEN1, MEN4 and SDH-related syn-
dromes, are less common [6–10].
FIPA families can be heterogeneous (when more than 
one type of pituitary adenoma is present in the same fam-
ily) or homogeneous [11]. In our cohort of 216 FIPA fami-
lies, 60% had at least one subject with GH excess (92% of 
the 37 AIP mutation positive families and 53% of the 179 
AIP mutation negative families). Twenty-eight percent of 
the whole cohort had homogenous GH FIPA (43% of the 
Abstract Acromegaly is caused by a somatotropinoma 
in the vast majority of the cases. These are monoclonal 
tumors that can occur sporadically or rarely in a familial 
setting. In the last few years, novel familial syndromes have 
been described and recent studies explored the landscape 
of somatic mutations in sporadic somatotropinomas. This 
short review concentrates on the current knowledge of the 
genetic basis of both familial and sporadic acromegaly.
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Introduction
Acromegaly is caused by excess growth hormone (GH) 
secreted from the pituitary gland most often due to a soma-
totropinoma. While somatotropinomas are monoclonal 
tumors that occur sporadically in the vast majority of the 
patients, acromegaly can also be part of a familial disease. 
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37 AIP mutation positive families and 24% of the 179 AIP 
negative families).
The genetic basis for the majority of FIPA cases is cur-
rently not known. A fifth of the families have germline 
mutations in the AIP gene [6, 12] and GPR101 mutations 
(duplications) have been described in two families [13] 
(Fig. 1).
AIP
Heterozygous loss-of-function AIP mutations predispose 
the appearance of young-onset pituitary adenomas with an 
incomplete (20–23%) penetrance [23]. About 50% of AIP 
mutations kindreds present as sporadic cases due to low 
penetrance rather than de novo mutations [6]. The preva-
lence of AIP mutations is doubled (36–40%) when consid-
ering homogeneous acromegaly/gigantism FIPA families 
compared to the frequency in all the FIPA families. Soma-
totropinomas, with or without prolactin co-secretion, repre-
sent the most common AIP mutation positive adenoma type 
followed by prolactinomas (Fig.  1). A few clinically non-
functioning adenomas have also been described but these 
usually show positive immunostaining for GH and prolac-
tin [6]. A few ACTH- and a single TSH-secreting adenoma 
have also been described [24]. Somatotropinomas harbor-
ing AIP mutations are more frequently macroadenomas 
(88%) with extrasellar extension, more frequent in younger 
patients (78% younger than <30 years) and present with 
a higher frequency of apoplexy especially in children [6, 
12, 25, 26]. A slight male preponderance has been shown 
earlier [12], but with extensive familial screening a more 
balanced picture is emerging [6]. Patients with AIP muta-
tion show poor response to somatostatin receptor ligands 
(SRLs) [12]. There are two hypothesis to explain this poor 
response: (i) first-generation SRLs increase AIP expression 
and, in turn, this can upregulate the tumor suppressor zinc-
finger protein ZAC1 which has been previously linked to 
SRLs anti-proliferative effects [27]. Interestingly, sporadic 
somatotropinomas without AIP mutations with low AIP 
protein expression also have a poor response to first-gener-
ation SRLs [28, 29]. Therefore, the lack or low level of AIP 
via the lack of ZAC1 upregulation could explain the resist-
ance to treatment with SRLs [4, 30]; (ii) another mecha-
nism for SRLs resistance of AIP mutation positive cases 
could be the low level of inhibitory G protein which has 
been identified both in embryonic fibroblast lacking AIP 
and human pituitary adenomas with AIP mutation [31].
The AIP gene is located at chromosome 11q13 and 
encodes a 330 amino acid protein suggested to be a 
tumor suppressor gene. AIP influences the cAMP path-
way [32] via inhibitory G proteins (Gαi2) [31], via phos-
phodiesterases [33, 34] and via interfering with down-
stream pathway of somatostatin receptors [30], but the 
exact mechanism how lack of AIP leads to somatotroph 
adenomas is unclear. Over 70% of pathogenic mutations 
identified to date lead to missing or truncated protein 
(frameshift, nonsense, small and large deletions, variants 
in the regulatory region with functional data on promoter 
activation supporting reduced activity), while missense 
mutations and in-frame small deletions and insertions 
can also occur mostly affecting the C terminal charac-
teristic tetratricopeptide domains [4, 24, 25]. Separating 
pathogenic variants from benign polymorphisms can be 
challenging in some cases. Several AIP sequence vari-
ants were tested in vitro using two-hybrid assay between 
PDE4A5 and AIP to help to identify pathogenicity of 
some of the questionable AIP variants [25, 33]. There 
are a few mutational hotspots in the AIP gene: the most 
common one affects the Arg304 residue, while Arg81 and 
Arg271 have also been described in independent cohorts 
[35].
The type of AIP mutation can influence the phenotype, 
with patients harboring truncating mutations being younger 
at diagnosis than those harboring full-length mutated pro-
teins [6]. Regarding mutant AIP proteins, it has been shown 
that many pathogenic missense AIP mutations have a sig-
nificantly reduced stability in experimental conditions [36]. 
This suggests that the mechanism of lack of function in 
these cases may be the rapid degradation of the (probably) 
misfolded protein [36].
AIP mutations can also be identified in sporadic acro-
megaly cases [6, 37–41]. Considering patients without any 
age limitations, only about 4% of the apparently sporadic 
patients will harbor a germline AIP mutation [40]. How-
ever, this is more frequent in young patients, especially 
those harboring macroadenomas, being found in up to 13% 
of patients younger than 30 years of age and can be found 
in up to 33% of pediatric (18 years) patients [39, 42]. The 
lack of family history is due to the incomplete penetrance 
as only one de novo acromegaly case has been described to 
date [43].
In the presence of an AIP mutation in a patient with 
apparently sporadic acromegaly, screening of the first-
degree relatives for the mutation should be performed [44]. 
Family member screening of AIP carriers was shown to 
identify 24% of ‘unaffected’ carriers with biochemical or 
radiological abnormalities, and, interestingly, half of these 
actually had symptoms but did not previously seek medical 
attention. We need to be cautious, however, as, similar to 
MEN1 screening, the small non-functioning lesions in AIP 
mutation carrier subjects may represent incidentalomas. 
Considering the prevalence of germline AIP mutations in 
young patients with apparently sporadic pituitary tumors, 
while no formal guidelines exist, several groups recom-
mend that screening for AIP mutations be performed in all 
patients diagnosed before 18  years of age and in patients 
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harboring a macroadenoma diagnosed before 30  years of 
age [24, 40, 44].
X‑linked acrogigantism (XLAG)
Patients with very early-onset gigantism may harbor an 
unusual type of mutation, a microduplication of chro-
mosome Xq26.3 (Fig.  1) [13]. The Xq26.3 region codes 
four genes, but only one of them, GPR101, coding for an 
orphan G-protein coupled receptor, was overexpressed in 
the patients with a microduplication of this region [13]. 
The causative role of this gene was reinforced by a case 
with typical phenotype but with a smaller microduplica-
tion only including the GPR101 gene [2]. Extensive search 
for Xq26.3 microduplication in pediatric or adult cases 
of GH excess could only identify this genetic abnormal-
ity in very early-onset (accelerated growth before the age 
of 5  years) gigantism cases. Altogether 31 patients have 
been reported to date, including two unrelated families 
and 26 sporadic cases [2, 13, 45–47]. The majority of the 
cases are females and harbor de novo mutations and pen-
etrance is 100% based on available data. Sporadic male 
cases described to date harbor mosaic mutations [2, 45, 
48]. Interestingly, diagnosis was challenging in a case of 
a 4 year old boy with pituitary hyperplasia and gigantism, 
where germline DNA showed no detectable duplication 
with CGH array and droplet PCR was not conclusive. The 
diagnosis was finally made using DNA derived from pitui-
tary tissue and skin biopsy showing the typical GPR101 
duplication [48]. Patients have a median age of disease 
onset of 1.0 year (ranging from 0.5 to 2.0 years), and were 
younger than those gigantism patients who did not pre-
sent the microduplication (median age of disease onset of 
16.0 years, ranging from 5.0 to 18.0 years) [1, 13]. XLAG 
patients represent the second largest group of patients with 
childhood-onset acromegaly, after AIP mutation positive 
patients and there is no phenotypic difference between 
mosaic or germline XLAG cases [1, 2, 45].
The GPR101 gene variant p.E308D was originally sug-
gested to play a role in acromegaly pathogenesis (11 out 
of 248 patients with acromegaly) (4.4%) [13], but exten-
sive data from different laboratories cannot confirm these 
data. A large study including 766 patients with apparently 
sporadic pituitary tumors found a frequency of 1.6% of 
germline GPR101 variants (three patients with acromeg-
aly, two with Cushing`s disease and one with a nonfunc-
tioning pituitary adenomas) [49, 50]. The observed allele 
frequency (0.49) was not different form the frequency pre-
sent in the general population [0.69, Exome Aggregation 
Consortium (ExAc) database (http://exac.broadinstitute.
org)] in another study which included 395 leukocyte- and 
193 somatotropinoma-derived samples [2]. A recent Italian 
study found no germline GPR101 variants in a cohort of 
215 patients with GH-secreting adenomas [38].
Multiple endocrine neoplasia types 1 and 4 (MEN1 
and MEN4)
Acromegaly can occur in the setting of a multiple endo-
crine neoplasia. In multiple endocrine neoplasia type 1 
(MEN1), pituitary adenomas are associated with hyper-
parathyroidism and neuroendocrine tumors of the pancreas 
[19]. Germline mutations in the MEN1 gene are found 
in 80–90% of the probands with familial MEN1 and in 
approximately 65% of the patients with sporadic MEN1 
[19, 51, 52]. MEN1 mutations were described in 1.2% of 
sporadic acromegaly patients younger than 30 years of age 
[51].
Primary hyperparathyroidism is the most common 
component of MEN1, being observed in over 90% of 
the cases. Pituitary tumors occur in 38% (15–50%) of 
the cases presenting with pituitary disease [10, 53, 54], 
with prolactinomas being the most frequent (60%) and 
somatotropinomas being the second most common (25%) 
(Fig. 1) [19]. Interestingly, a prospective screening study 
found different proportions of pituitary disease subtypes 
Fig. 1  For each of the syndromes, the left pie represents the percent-
age of pituitary adenomas in patients with the disease. The middle pie 
represents the percentage of patients with GH excess and the right pie 
shows the proportion of patients with acromegaly or gigantism. AIP: 
20 to 23% of gene carriers manifest the disease, all affected patients 
have a pituitary adenoma and 86% of these result in GH excess 
[6]. Overall 48% of GH excess patients have gigantism [6], but in a 
homogenous R304* cohort 58% had gigantism [14] confirming that 
truncating mutation patients have lower age of onset of disease [6]. 
XLAG: All gene carriers develop pituitary disease, 83% adenoma 
and 17% hyperplasia and all have gigantism [15]. Carney complex: 
80% of gene carriers will have biochemical GH abnormality and 
10% will manifest clinical acromegaly [16]. A few patient have been 
described with gigantism. McCune-Albright syndrome: 70% of gene 
carriers will have GH excess and 36% of these would have gigantism 
[17]. MEN1: 40% of MEN1 gene mutation carriers have a pituitary 
adenoma and 25% of these have acromegaly, with very few cases 
described in children [18, 19]. We note, however, that in a system-
atic screening study [10] a large number of small NFPAs have been 
identified and the percentage of acromegaly is only 7% among the 
pituitary adenoma patients in this study. GHRH-secreting pancreas 
tumors can also lead to acomegaly or gigantism in MEN1 patients. 
MEN4: Among the very few patients and unaffected family members 
described with CDKN1B mutation 4/5th of the patients were affected 
(this could be ascertainment bias and more data is needed to iden-
tify true penetrance), 63% of the affected subjects (30% of all carri-
ers) had pituitary disease and 2/3 of these (5 cases) had GH excess 
with one of these having gigantism. Interestingly, in two of the five 
GH excess cases, the mutation was located in the 5′UTR (untrans-
lated region) [20, 21]. 3PAs: As the penetrance of an abnormality in 
the various SDH subtype mutation carriers can be different, we show 
here penetrance data ~50% for SDHB mutations. Among the affected 
subjects very low percentage of SDHx carriers have a pituitary ade-
noma (<1%). Out of 15 cases reviewed four (28%) had acromegaly, 
none of them were childhood-onset [22]
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with significantly higher number non-functioning adeno-
mas. These differences might be explained by the differ-
ent strategies used to collect the data (spontaneous pres-
entation vs. clinical screening) [10] and it is unclear what 
percentage of these often small non-functioning adeno-
mas represent, in fact, incidentalomas. Pituitary tumors 
in MEN1 occur more frequently in women, prolactino-
mas are more common in younger patients and are often 
invasive macroadenomas. In MEN1 patients with acro-
megaly, the diagnosis is usually made after 40 years of 
age [19]. Although three patients with MEN1-associated 
acromegaly are reported to be treated medically, no data 
are available of their SRLs responsiveness [8]. In MEN1 
patients with acromegaly and enlarged pituitary gland 
with no discernable pituitary adenoma, a GHRH-secret-
ing neuroendocrine tumor, typically arising from the 
pancreas should also be considered [55]. Co-existance 
of acromegaly due to GHRH-secreting neuroendocrine 
tumor and a prolactinoma has also been described in 
MEN1 syndrome, representing a significant diagnostic 
challange [56]. Circulating GHRH measurement is now 
routinely available in reference laboratories [55].
The tumor suppressor gene MEN1 is located at chromo-
some 11q13 coding for the protein menin. MEN1 exhibits 
an autosomal dominant inheritance pattern [19, 57]. To 
date, the exact mechanism by which inactivating MEN1 
mutation leads to tumorigenesis is unknown, but menin has 
been shown to influence numerous relevant processes such 
as the cell cycle, cell division, genome stability and tran-
scriptional regulation [57]. The last detailed review iden-
tified 1133 different germline and 203 somatic mutations 
without typical hotspots [51], although codons 139, in exon 
2, and 418 in exon 9, were affected by the highest number 
of mutations (seven different mutations) [51]. Regarding 
the type of mutations, 26% were missense mutations, 14% 
were nonsense mutations, 42% were frameshift insertions 
or deletions, 5.5% were in-frame insertions or deletions, 
10% were splice site mutations and 2.5% were large dele-
tions [51, 52]. Screening for MEN1 mutations in patients 
with acromegaly should be considered in the presence of 
other features of the syndrome or in the presence of a fam-
ily history of MEN1 [57, 58].
Rarely patients with MEN1 phenotype, but without 
MEN1 mutations, harbor mutations in the cyclin-depend-
ent kinase inhibitor 1B (CDKN1B) gene coding for  p27kip1 
protein [9, 59]. This syndrome is named multiple endo-
crine neoplasia type 4 (MEN4) and only nine cases have 
been described with pituitary adenomas. Five of the nine 
reported MEN4-related pituitary disease is acromegaly 
(Fig.  1). Therefore, in an acromegaly/gigantism patient 
with features of the MEN1 syndrome but without MEN1 
mutations, screening for CDKN1B mutations is indicated 
[58].
Carney complex
Carney complex (CNC) is a syndrome characterized by 
the presence of acromegaly (10–12%), cardiac and cutane-
ous myxomas, primary pigmented nodular adrenocortical 
disease (PPNAD) and pigmented lesions of the skin and 
mucosae (can vary from lentigines to blue nevi) [16]. CNC 
presents as familial disease in 70% of the cases and is inher-
ited in an autosomal dominant manner with an overall full 
penetrance. GH excess is present in 80% of the cases and is 
mainly consequence of a pituitary somatotroph hyperplasia 
and not due to a pituitary adenoma (Fig. 1) [16].
The cause of the majority of CNC cases is a mutation 
in the PRKAR1A gene, coding for the regulatory subunit 
type I alpha of the protein kinase A, located at chromosome 
17q24 [60, 61]. A second genetic locus associated with 
CNC has been described in chromosome region 2p16, but 
the specific genetic defect has not been elucidated [16, 61]. 
A single case of gene duplication affecting the catalytic B 
subunit of PKA has also been described [62].
Acromegaly and paraganglioma/phaeochromocytoma 
syndrome
The coexistence of acromegaly with paragangliomas 
(PGLs) or phaeochromocytomas has been described since 
1952 [63]. As they are both rare tumors, the occurrence of 
both in the same patient can be coincidental but attention 
in the recent years has been given for a possibly common 
genetic basis, for the recently named “3PAs” syndrome 
(paragangliomas, phaeochromocytomas and pituitary ade-
nomas) [64].
Considering that mutations in the genes coding the suc-
cinate dehydrogenase (SDH) complex are the most com-
mon genetic causes of PGLs/phaeochromocytomas it has 
been studied in the cases of 3PAs [22, 64, 65]. Following 
description of a succinate dehydrogenase type B (SDHB) 
mutation positive patient with a pituitary adenoma [66] and 
SDHB mutation positive familial PGLs and macroprolacti-
nomas [67], somatotroph adenomas have also been associ-
ated with SDH mutations (SDHA, SDHB and SDHD) [64, 
65, 68, 69].
In some cases, the 3PAs syndrome occurs in the absence 
of mutations in the SDH complex genes [22]. Mutations 
in genes causing other familial syndromes may be found 
and, actually, there is a reported case with mutation in the 
MEN1 and other case with mutation in the RET gene [65, 
70].
McCune‑Albright syndrome
Patients with McCune-Albright syndrome may present as 
sporadic acromegaly or gigantism. They harbor a mosaic 
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mutation in the GNAS gene coding for the alpha-subunit 
of the G-stimulatory protein (Gαs). McCune-Albright syn-
drome characterized by the development of polyostotic 
fibrous dysplasia, café-au-lait spots and endocrine hyper-
function, including precocious puberty, thyrotoxicosis 
due to autonomous thyroid nodules, Cushing`s syndrome 
(caused by nodular adrenal hyperplasia) and GH excess 
or manifest acromegaly/gigantism [71, 72]. Excess of GH, 
often with prolactin co-secretion, is observed in approxi-
mately 20% of the cases. In the majority of the cases 
pituitary hyperfunction is caused by pituitary hyperplasia 
and not by an adenoma [72]. The diagnosis of McCune-
Albright syndrome, thus, should be suspected in acromeg-
aly/gigantism patients with other features of the syndrome.
The GNAS gene is located at chromosome 20q13.3. 
Mutations in the GNAS gene have been described more fre-
quently at codon 201 (Arg201 for Cys or His or Ser) than at 
codon 227 (Gln227 for Arg or Leu) [73–75]. These muta-
tions lead to loss of GTPase activity of the G-stimulatory 
protein alpha subunit while leaving the adenyl cyclase stim-
ulatory activity intact. The resulting constitutive activation 
and increased intracellular cAMP levels lead to somato-
troph proliferation/hyperplasia and GH hypersecretion [76].
GH excess in neurofibromatosis type 1
GH excess has been described in both pediatric and adult 
patients with neurofibromatosis leading to gigantism or 
acromegaly ([77–80] and references within). Although 
most cases are associated with optic gliomas and no pitu-
itary tumors, a few has been described with GH positive 
pituitary adenomas and it is unclear if the latter ones are 
pure coincidences or not.
Somatic changes in somatotropinomas
The most common somatic mutation in acromegaly are 
the activating mutations of the GNAS gene [76], with a 
frequency of about 40% (ranging from 10 to 50% depend-
ing on the ethnical background) [73, 74, 81–83]. Somatic 
GNAS mutations are found with equal frequency in both 
sexes and are more frequent in tumors from older patients 
[73, 83]. They are also more common in smaller tumors 
that secrete higher GH levels and are associated with a 
densely granulated pattern in the histopathology analysis 
[75, 84].
Some studies suggest that tumors harboring a GNAS 
mutation present a better response to first-generation 
SRLs, but this finding is not homogeneous in the litera-
ture [74, 83–85]. Recently, a meta-analysis including 
eight studies and 315 patients concluded that patients 
with a GNAS mutation present a higher reduction of GH 
levels during the acute octreotide suppression test [75]. 
However, studies addressing the response to long-term 
SRLs treatment present conflicting results [74, 84].
To identify further somatic mutations in sporadic soma-
totroph adenomas exome [83, 86] and whole genome 
sequencing studies were performed [87]. Välimäki et  al. 
performed a whole-genome sequencing and single-nucleo-
tide polymorphism (SNP) array in 12 fresh-frozen somato-
tropinomas and in the leucocyte DNA of the corresponding 
patients [87]. The whole-genome sequencing showed an 
average of 129 somatic nucleotide variants (SNV), with an 
average of 2.3 SNV per tumor. However, the only recurrent 
somatic events were GNAS mutations and shared chromo-
some losses (chromosomes 1, 6, 13, 14, 15, 16, 18 and 22). 
No novel recurrent mutated genes were identified. In agree-
ment with these findings, Ronchi et  al. performed a next-
generation whole-exome sequencing in 36 sporadic soma-
totropinomas, identifying a median of three mutations per 
sample [86]. Again, the only recurrent somatic mutation 
observed was in the GNAS gene (31.4% of the cases). More 
recently, Song et  al. performed whole-exome sequenc-
ing and copy number analysis in 125 pituitary adenomas, 
including 20 somatotropinomas [83]. They observed GNAS 
mutations in 55% of the tumors. Interestingly, copy number 
variation was also found affecting the chromosome 20q13.3 
region, where the GNAS gene is located, in 8/20 samples, 
5 of those also had a single nucleotide GNAS mutation. 
However, the 20q13.33 locus contains synaptonemal com-
plex protein 2 (SYCP2), a cohesion complex gene, while 
other cohesion complex genes were also found amplified 
in somatotroph adenomas:SYPC1 on chromosome 1p13.2 
was amplified in 11/20 somatotroph samples and RAD21 
cohesin complex component like 1 (RAD21L1) on chromo-
some 20p13 was amplified in 4/20. While data from inde-
pendent cohort and functional characterization is needed, 
these results raise the possibility that cohesion complex 
might play a role in pituitary adenoma genesis [88].
These studies altogether identified three possible path-
ways involved in somatotroph tumorigenesis: the cAMP, 
the calcium-channel signaling and the cohesin pathways. 
In the study by Ronchi et al., seven genes involved in the 
cAMP signaling pathway were affected in 14 of the 36 
samples and eight samples harbored variants in genes 
involved in the calcium signaling or metabolism [86]. In 
the study by Välimäki et al., five genes involved in cAMP 
or calcium-related signaling pathways were found to be 
mutated [87]. As an increase in cAMP levels is associ-
ated with an increase in cytosolic free calcium and this 
triggers the GH secretion, it is probably that genetic and/
or epigenetic alterations in these pathways lead to the 
development of somatotropinomas. In the Song et  al. 
study 13/20 samples had changes in the cohesion path-
way members [83].
17Pituitary (2017) 20:10–21 
1 3
Conclusion
Acromegaly is caused in the majority of the cases by a spo-
radic somatotropinoma and rarely by pituitary hyperplasia. 
In 95% of the cases it occurs sporadically but almost 50% 
of the childhood-onset cases have an identifiable genetic 
background, most commonly AIP or GPR101 mutations. 
Acromegaly is one of the most frequent pituitary adenoma 
types which occur in a familial setting most commonly 
due to AIP mutations. Genetic screening has been shown 
to identify family members in an earlier stage of the dis-
ease which is predicted to lead to better long-term out-
come. Therefore genetic testing and counselling of family 
members will improve the long-term management of this 
disease.
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